Interruption of the enterohepatic circulation of digitoxin by cholestyramine
Open Access
- 1 December 1971
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 50 (12) , 2638-2644
- https://doi.org/10.1172/jci106764
Abstract
Previous studies of digitalis glycoside metabolism and excretion have indicated that these compounds undergo a significant enterohepatic cycle in some species. It has been suggested that the existence of such a cycle in man contributes to the prolonged action of certain cardiac glycosides. Previous studies have demonstrated that cholestyramine binds digitoxin and digoxin in vitro and accelerates the metabolic disposition of digitoxin in rats and guinea pigs, presumably by interrupting the enterohepatic circulation. In order to assess the role of the enterohepatic circulation in the metabolism of digitalis glycosides in humans, maintenance doses of cholestyramine were administered to 7 of 15 normal human subjects beginning 8 hr after digitalization with 1.2 mg of digitoxin-3H. All subjects had frequent measurements of serum radioactivity, left ventricular ejection time (LVET), and electromechanical systole (QS2), the latter recorded as the interval from onset of Q wave to first major component of second heart sound. Measurement of the LVET and QS2 intervals affords a sensitive index of the cardiac response to digitalis. In addition, chloroform extraction of serum was performed to separate unchanged digitoxin and active metabolites from cardioinactive metabolites of digitoxin. Cholestyramine treatment resulted in reduction in half-life to total serum radioactivity from 11.5 to 6.6 days, and in chloroform-extractable radioactivity from 6.0 to 4.5 days, as compared to controls. In addition, cholestyramine treatment was accompanied by more rapid return to base line values of digitoxin-induced changes in the LVET and QS2 intervals. A significant positive correlation was found between QS2 values and chloroform-extractable radioactivity, the latter reflecting unchanged digitoxin-H3 (r=0.64; P=<0.01). The results indicate that administration of cholestyramine to digitalized human subjects accelerates the metabolic disposition of digitoxin and abbreviates the physiologic response to the glycoside. This effect is presumably mediated by interruption of the enterohepatic circulation of digitoxin by cholestyramine.Keywords
This publication has 10 references indexed in Scilit:
- Current Techniques for Serum or Plasma Digitalis Assay and Their Potential Clinical ApplicationThe Lancet Healthy Longevity, 1970
- An Improved Method of Digitoxin TherapyAnnals of Internal Medicine, 1970
- Effect of Digitalis on Systolic Time Intervals in Heart FailureThe Lancet Healthy Longevity, 1970
- Intestinal absorption of six tritium-labeled digitalis glycosides in rats and guinea pigs.1969
- The Clinical Pharmacology of Digitalis GlycosidesThe Lancet Healthy Longevity, 1968
- SPECIES DIFFERENCE IN DURATION OF ACTION OF CARDIAC GLYCOSIDES1967
- Double isotope dilution derivative assay of digitoxin in plasma, urine, and stool of patients maintained on the drug.Journal of Clinical Investigation, 1966
- BIOTRANSFORMATION OF DIGITOXIN IN DOG1966
- Excretion of radioactive digitoxin by the dog.1965
- METABOLIC FATE OF RADIOACTIVE DIGITOXIN IN HUMAN SUBJECTS1955